5329892025-07-012025-09-305329892025-09-305329892025-03-315329892025-04-012025-09-305329892025-07-012025-09-30in-capmkt:OtherExpenses1Member5329892025-07-012025-09-30in-capmkt:OtherExpenses2Member5329892025-04-012025-09-30in-capmkt:OtherExpenses1Member5329892025-04-012025-09-30in-capmkt:OtherExpenses2Member5329892025-07-012025-09-30RelatedPartyTransactionDomain15329892025-06-30RelatedPartyTransactionDomain15329892025-09-30RelatedPartyTransactionDomain15329892025-07-012025-09-30RelatedPartyTransactionDomain25329892025-06-30RelatedPartyTransactionDomain25329892025-09-30RelatedPartyTransactionDomain25329892025-07-012025-09-30RelatedPartyTransactionDomain35329892025-06-30RelatedPartyTransactionDomain35329892025-09-30RelatedPartyTransactionDomain35329892025-07-012025-09-30RelatedPartyTransactionDomain45329892025-06-30RelatedPartyTransactionDomain45329892025-09-30RelatedPartyTransactionDomain45329892025-07-012025-09-30RelatedPartyTransactionDomain55329892025-06-30RelatedPartyTransactionDomain55329892025-09-30RelatedPartyTransactionDomain55329892025-07-012025-09-30RelatedPartyTransactionDomain65329892025-06-30RelatedPartyTransactionDomain65329892025-09-30RelatedPartyTransactionDomain65329892025-07-012025-09-30RelatedPartyTransactionDomain75329892025-06-30RelatedPartyTransactionDomain75329892025-09-30RelatedPartyTransactionDomain75329892025-07-012025-09-30RelatedPartyTransactionDomain85329892025-06-30RelatedPartyTransactionDomain85329892025-09-30RelatedPartyTransactionDomain85329892025-07-012025-09-30RelatedPartyTransactionDomain95329892025-06-30RelatedPartyTransactionDomain95329892025-09-30RelatedPartyTransactionDomain95329892025-07-012025-09-30RelatedPartyTransactionDomain105329892025-06-30RelatedPartyTransactionDomain105329892025-09-30RelatedPartyTransactionDomain105329892025-07-012025-09-30RelatedPartyTransactionDomain115329892025-06-30RelatedPartyTransactionDomain115329892025-09-30RelatedPartyTransactionDomain115329892025-07-012025-09-30RelatedPartyTransactionDomain125329892025-06-30RelatedPartyTransactionDomain125329892025-09-30RelatedPartyTransactionDomain125329892025-07-012025-09-30RelatedPartyTransactionDomain135329892025-06-30RelatedPartyTransactionDomain135329892025-09-30RelatedPartyTransactionDomain135329892025-07-012025-09-30RelatedPartyTransactionDomain145329892025-06-30RelatedPartyTransactionDomain145329892025-09-30RelatedPartyTransactionDomain145329892025-07-012025-09-30RelatedPartyTransactionDomain155329892025-06-30RelatedPartyTransactionDomain155329892025-09-30RelatedPartyTransactionDomain155329892025-07-012025-09-30RelatedPartyTransactionDomain165329892025-06-30RelatedPartyTransactionDomain165329892025-09-30RelatedPartyTransactionDomain165329892025-07-012025-09-30RelatedPartyTransactionDomain175329892025-06-30RelatedPartyTransactionDomain175329892025-09-30RelatedPartyTransactionDomain175329892025-07-012025-09-30RelatedPartyTransactionDomain185329892025-06-30RelatedPartyTransactionDomain185329892025-09-30RelatedPartyTransactionDomain185329892025-07-012025-09-30RelatedPartyTransactionDomain195329892025-06-30RelatedPartyTransactionDomain195329892025-09-30RelatedPartyTransactionDomain19iso4217:INRiso4217:INRxbrli:shares532989BAFNAPHNOTLISTEDINE878I01022BAFNA PHARMACEUTICALS LIMITEDMain BoardEquity2025-04-012026-03-312025-11-112025-11-06INRLakhsQuarterlySecond quarterSingle segmentPharmaceuticals2025-11-1114:30:002025-11-1115:46:00trueCash Flow IndirectNot applicabletruetrueNANAfalsetrue2025-05-26www.bafnapharma.comfalsefalseThe Company has not defaulted on repayment of Loans and Debt Securities.2025-07-012025-09-30UnauditedStandalone354682000117970003664790001855830006279000-11209000549050008643000147270007630200033523000031249000031249000000031249000000031249000-46200030787000236563000101.321.32001.321.32Notes <BR> 1. The above unaudited financial results for the quarter and half year ended 30th September, 2025 have been reviewed by the Audit Committee and thereafter approved by the Board of Directors of the Company at their meetings held on 11th November 2025. The Statutory Auditors have conducted a Limited Review of these financial results in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. <BR> 2. The figures for the quarter ended 30th September, 2025 and preceding quarter ended 30th September, 2024 are the balancing figures between unaudited year to date figures for the half year ended 30th September and the unaudited published figures for the 3 months ended 30th June of the respective financial years. <BR> 3. The figures for the corrosponding previous periods have been regrouped and reclassified whereever necessary, to make them comparable. <BR> 4. The above unaudited financial results have been prepared in accordance with Indian Accounting Standard 34 Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. <BR> 5. Company's business relates to the manufacturing of pharmaceuticals formations, which in context of Indian Accounting Standard 108 (Ind AS 108) as notified under Section 133 of the Companies Act, 2013 is considered as the only segment. <BR> 6. Exceptional items for the year ended 31st March 2025 represents the following <BR> (a) Derecognition of certain inventory items amounting to INR 37.56 Lakhs <BR> (b) Derecognition of Intangible Asset under Development amounting to INR 177 Lakhs. The management has derecognised the Intangible Asset under Development as it does not foresee that any future economic benefit would accrue to the Company in respect of the expenditure incurred in the earlier financial years towards obtaining certain product registrations.2025-04-012025-09-30UnauditedStandalone700922000177530007186750003611620006279000-13405000111304000176970002842600014207400065353700065138000065138000000065138000000065138000-92400064214000236563000102.752.75002.752.75Manufacturing Expenses49962000Other Expenses26340000Manufacturing Expenses100758000Other Expenses4131600065000900014666600000000050000094890009494000008061690003099860000325661000254400001081000171260003464120003377000140883000800658000001606827000236563000675716000912279000912279000193291000000019329100047820000018314000216387000130737000424690002177660002602350002907800042005000041856000162550000047816100000694548000160682700017696000-29126000758620000-83660000-851000-185480000-492180000141610000284260000-38740000336200000052400000000-61400002838600093524000000399000093125000000000001451300016417000000000000000000000052400000-1491330000000000042045000000178200000024225000-317830000-3178300034327000254400046200092400000-462000-924000BAFNA PHARMACEUTICALS LIMITED******Bafna Mahaveer Chand******Chief Executive OfficerRemuneration7800000Approved360000000BAFNA PHARMACEUTICALS LIMITED******Bafna Mahaveer Chand******Chief Executive OfficerLoanApproved0-15007000-15007000BAFNA PHARMACEUTICALS LIMITED******Navin Bafna******Son of Chief Executive OfficerAny other transactionSalary For Rendering Services2800000Approved137000000BAFNA PHARMACEUTICALS LIMITED******Navin Bafna******Son of Chief Executive OfficerAny other transactionSalary AdvanceApproved01300000BAFNA PHARMACEUTICALS LIMITED******Navin Bafna******Son of Chief Executive OfficerAny other transactionSalary Advance RepaymentApproved13000000BAFNA PHARMACEUTICALS LIMITED******Sasikala Bafna******Wife of Chief Executive OfficerAny other transactionRent1800000Approved88500000BAFNA PHARMACEUTICALS LIMITED******Shanmugam Hemalatha******Whole Time DirectorRemuneration2200000Approved100100000BAFNA PHARMACEUTICALS LIMITED******Vinayak Dinesh Dendukuri******Whole Time DirectorRemuneration4000000Approved165600000BAFNA PHARMACEUTICALS LIMITED******Melagiri Sridhar******Chief Financial OfficerRemuneration1700000Approved74700000BAFNA PHARMACEUTICALS LIMITED******Melagiri Sridhar******Chief Financial OfficerAny other transactionSalary AdvanceApproved3500000280000BAFNA PHARMACEUTICALS LIMITED******Melagiri Sridhar******Chief Financial OfficerAny other transactionSalary Advance RepaymentApproved7000000BAFNA PHARMACEUTICALS LIMITED******Mohanachandran A******Company SecretaryRemuneration1400000Approved56700000BAFNA PHARMACEUTICALS LIMITED******Palamadai Krishnan Sundaresan******Independent DirectorAny other transactionSitting FeesApproved15600000BAFNA PHARMACEUTICALS LIMITED******Ravichandran Chitra******Independent DirectorAny other transactionSitting FeesApproved22200000BAFNA PHARMACEUTICALS LIMITED******Akila Chintalapati Raju******Non Executive DirectorAny other transactionSitting FeesApproved4400000BAFNA PHARMACEUTICALS LIMITED******Upendar Mekala Reddy******Non Executive DirectorAny other transactionSitting FeesApproved17800000BAFNA PHARMACEUTICALS LIMITED******Navin Kumar******Independent DirectorAny other transactionSitting FeesApproved6700000BAFNA PHARMACEUTICALS LIMITED******Bhansilal And Co******Relative of KMPAny other transactionLease Rent12000Approved600000BAFNA PHARMACEUTICALS LIMITED******Mahaveer Chand Bafna HUF******Relative of KMPAny other transactionLease Rent6500000Approved30000000-300000014049000